FC
AXSM icon

FORA Capital’s Axsome Therapeutics AXSM Stock Holding History

FORA Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Sell
1,450
-4,264
-75% -$737K 0.02% 381
2025
Q4 		$740K Buy
+5,714
New +$798K 0.09% 249
2025
Q2 		– Sell
-7,633
Closed -$890K – 511
2025
Q1 		$890K Buy
+7,633
New +$870K 0.09% 249
2024
Q4 		– Sell
-11,058
Closed -$994K – 394
2024
Q3 		$994K Buy
+11,058
New +$965K 0.12% 214
2024
Q1 		– Sell
-8,907
Closed -$709K – 408
2023
Q4 		$709K Buy
+8,907
New +$595K 0.06% 291
2022
Q4 		– Sell
-4,505
Closed -$201K – 464
2022
Q3 		$201K Sell
4,505
-11,713
-72% -$585K 0.04% 384
2022
Q2 		$621K Buy
16,218
+7,476
+86% +$236K 0.12% 209
2022
Q1 		$350K Buy
+8,742
New +$271K 0.06% 354
2021
Q3 		– Sell
-786
Closed -$53K – 393
2021
Q2 		$53K Buy
+786
New +$47.2K 0.01% 699
2021
Q1 		– Sell
-5,237
Closed -$427K – 776
2020
Q4 		$427K Buy
5,237
+4,925
+1,579% +$368K 0.07% 319
2020
Q3 		$22K Sell
312
-6,193
-95% -$483K 0.01% 571
2020
Q2 		$535K Buy
+6,505
New +$501K 0.18% 145

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's AXSM Position: Q1 2026 in Review

FORA Capital reduced its Axsome Therapeutics (AXSM) stake by 75% in Q1 2026, selling an estimated $737K and leaving 1,450 shares worth $245K. The position accounts for 0.02% of the portfolio, ranked #381.

FORA Capital first reported a position in AXSM in Q2 2020 and has held it in 12 quarters since. The position peaked at $994K in Q3 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • FORA Capital held 1,450 shares of Axsome Therapeutics worth $245K as of Q1 2026.
  • FORA Capital sold 4,264 Axsome Therapeutics shares in Q1 2026, an estimated $737K.
  • Axsome Therapeutics made up 0.02% of FORA Capital's portfolio in Q1 2026, its #381 holding.
  • FORA Capital first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • FORA Capital's Axsome Therapeutics position peaked at $994K in Q3 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.